Dawson James analyst Jason Kolbert reiterated a Neutral rating on Adamis Pharmaceuticals (NASDAQ: ADMP) The analyst quotes: "In August 2020 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE